Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors

Fabrice Barlesi; Pascale Tomasini

doi:10.1016/S1470-2045(20)30207-2

Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors

Fabrice Barlesi, Pascale Tomasini

Résultats de recherche: Contribution à un journal › !!Comment/debate

15 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	607-608
Nombre de pages	2
journal	The Lancet Oncology
Volume	21
Numéro de publication	5
Les DOIs	https://doi.org/10.1016/S1470-2045(20)30207-2
état	Publié - 1 mai 2020

Accès au document

10.1016/S1470-2045(20)30207-2

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{6bea7faec754418e823535aa4c227a53,

title = "Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors",

author = "Fabrice Barlesi and Pascale Tomasini",

note = "Funding Information: FB reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology, Hoffmann–La Roche, Novartis, Merck, Merck Sharp & Dohme, Pierre Fabre, Pfizer, and Takeda, outside the submitted work. PT reports grants and non-financial support from Roche, Astra Zeneca, BMS, BI, and Takeda, outside the submitted work.",

year = "2020",

month = may,

day = "1",

doi = "10.1016/S1470-2045(20)30207-2",

language = "English",

volume = "21",

pages = "607--608",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "5",

}

TY - JOUR

T1 - Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors

AU - Barlesi, Fabrice

AU - Tomasini, Pascale

N1 - Funding Information: FB reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology, Hoffmann–La Roche, Novartis, Merck, Merck Sharp & Dohme, Pierre Fabre, Pfizer, and Takeda, outside the submitted work. PT reports grants and non-financial support from Roche, Astra Zeneca, BMS, BI, and Takeda, outside the submitted work.

PY - 2020/5/1

Y1 - 2020/5/1

UR - http://www.scopus.com/inward/record.url?scp=85083880507&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(20)30207-2

DO - 10.1016/S1470-2045(20)30207-2

M3 - Comment/debate

C2 - 32251624

AN - SCOPUS:85083880507

SN - 1470-2045

VL - 21

SP - 607

EP - 608

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 5

ER -